Sort
89,613 grants matching “depression”
PHARMACOGENETICS OF MEMBRANE TRANSPORTERS
$2,722,408University Of California San Francisco · U01 · FY2004 · GM
Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)
$2,721,668Deepak Cyril D'souza · Yale University · U01 · FY2019 · DA
New, GK-12: Ingenuity Incubators Develop NSF Fellow Potential and Prepare Tech Students for Engineering
$2,721,405Douglas J Cooper · University Of Connecticut · · FY2010 · EDU
Section on Light and Circadian Rhythms
$2,718,151Samer Hattar · National Institute Of Mental Health · ZIA · FY2023 · MH
EMORY CONTE CENTER FOR NEUROSCIENCE OF MENTAL DISORDERS
$2,717,105Emory University · P50 · FY2000 · MH
Structure and Function of Neuronal Hemichannels
$2,716,377Hiroyasu Furukawa · Cold Spring Harbor Laboratory · RF1 · FY2019 · NS
Frontal Striatal Systems and Dopamine in Normal and Pathological Behavior
$2,713,014Bruno Averbeck · National Institute Of Mental Health · ZIA · FY2024 · MH
Screening, Tracking and Treatment for Anxiety and Depression in Community Colleges
$2,712,362Michelle G Craske · University Of California Los Angeles · P50 · FY2025 · MH
Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?
$2,708,839Kyle Matthew Kampman · University Of Pennsylvania · UH3 · FY2024 · DA
A Long-Acting Bioabsorbable Naltrexone Subcutaneous Implant for Opioid Use Disorder
$2,708,703Steven M Cohen · Drug Delivery Company, Llc, The · UH3 · FY2025 · DA
GENERAL CLINICAL RESEARCH CENTER
$2,705,036University Of New Mexico · M01 · FY2002 · RR
A Long-Acting Bioabsorbable Naltrexone Subcutaneous Implant for Opioid Use Disorder
$2,700,832Steven M Cohen · Drug Delivery Company, Llc, The · UG3 · FY2020 · DA
CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse
$2,700,000Georgette Suidan · Cerevel Therapeutics, Llc · UH3 · FY2024 · DA
CVL-354, a kappa opioid receptor antagonist for treatment of opioid use disorder, withdrawal and relapse
$2,700,000Philip Iredale · Cerevel Therapeutics, Llc · UH3 · FY2023 · DA
Mouse models of stress disorders and addiction
$2,698,880Andrew Holmes · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2022 · AA
The impact of changes in social determinants of health on adolescent and young adult mental health during the COVID-19 pandemic: A longitudinal study of the Asenze cohort in South Africa
$2,696,906Jeremy Calvin Kane · Columbia University Health Sciences · RF1 · FY2023 · MH
Collaborative Research: The Cariaco Basin Oceanographic Time Series Program
$2,695,079Frank E Muller-Karger · University Of South Florida · · FY2003 · GEO
Intersectional Strategies to Understand the Function of Diverse Neural Circuits
$2,692,500Lindsay A Schwarz · St. Jude Children'S Research Hospital · DP2 · FY2019 · NS
Development of a Safer and More Effective Ibogaine Analog for the Treatment of Opioid Use Disorder
$2,692,397Gerard Joseph Marek · Gilgamesh Pharmaceuticals Inc · UG3 · FY2025 · DA
Immunotherapy targeting the HPA axis in Alzheimerâs disease
$2,689,784Todd E. Golde · University Of Florida · RF1 · FY2019 · AG
Soluble αSyn is a modulator of AD pathophysiology
$2,689,594Sylvain E. Lesne · University Of Minnesota · RF1 · FY2019 · AG
Glutamatergic Modulators for Rapid & Sustained Antidepressant Effect
$2,688,794Carlos Zarate · National Institute Of Mental Health · ZIA · FY2013 · MH
Social-Emotional Contexts of Adolescent Smoking Patterns
$2,687,275Robin J Mermelstein · University Of Illinois At Chicago · P01 · FY2006 · CA
Social-Emotional Contexts of Adolescent Smoking Patterns
$2,685,763Robin J Mermelstein · University Of Illinois At Chicago · P01 · FY2008 · CA
Family Study of Affective and Anxiety Spectrum Disorders
$2,684,537Kathleen R Merikangas · National Institute Of Mental Health · ZIA · FY2021 · MH